Who
James G. McArthur
President and CEO
Company insider
Files Form 4 as: President and CEO, PepGen; Director, Enliven Therapeutics; Director, Nightstar Therapeutics.
In numbers
- Trades disclosed
- 50
- Buys
- 3
- Sells
- 6
- Bought
- $68K
- Sold
- $571K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 25 Jan 2019
- Last trade
- 4 Mar 2026
- Last filed
- 6 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Mar 2026filed 6 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Sold | $32K5,144 at $6.23 | filing |
| 4 Mar 2026filed 6 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Sold | $829131 at $6.33 | filing |
| 4 Mar 2026filed 6 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Sold | $32K5,144 at $6.23 | filing |
| 4 Mar 2026filed 6 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Sold | $829131 at $6.33 | filing |
| 1 Mar 2026filed 2 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Code A | —187,688 at $0.00 | filing |
| 1 Mar 2026filed 2 Mar 2026 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —731,250 at $0.00 | filing |
| 1 Mar 2026filed 2 Mar 2026 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —731,250 at $0.00 | filing |
| 1 Mar 2026filed 2 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Code A | —187,688 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code D | —352,705 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —352,705 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,815 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,815 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,815 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,815 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,815 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,815 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code D | —466,095 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —466,095 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code D | —275,000 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.